Prediction of subclinical renal allograft rejection by vascular endothelial growth factor in serum and urine.

Abstract

It is first reported that the monitoring of VEGF in serum and urine might be a new noninvasive approach to supplement a protocol biopsy for detection of subclinical rejection.